Latest news
FDA panel to review Grail's blood-based cancer test - FirstWord PHARMAFirstWord PHARMA · Fri, 07 Aug 2026 21:32:11 GMTAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - The Cancer LetterThe Cancer Letter · Fri, 07 Aug 2026 20:50:43 GMTFDA sets advisory panel for Galleri multicancer screening test - MedTech DiveMedTech Dive · Fri, 07 Aug 2026 17:39:34 GMTGRAIL to face FDA AdCom for Galleri cancer test (GRAL:NASDAQ) - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 15:43:36 GMTGRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test - PR NewswirePR Newswire · Fri, 07 Aug 2026 15:05:00 GMTFDA Approves Replimune Skin Cancer Drug After Rejections - MedscapeMedscape · Fri, 07 Aug 2026 13:27:22 GMTGRAIL Bets Its Galleri Panel Will Set The FDA Bar For Future MCEDs - insights.citeline.cominsights.citeline.com · Fri, 07 Aug 2026 12:26:38 GMTFDA panel’s peptide vote raises alarms among Phoenix-area health experts - AZ FamilyAZ Family · Fri, 07 Aug 2026 03:43:00 GMT